Results of the SCORPION Trial with Anna Fagotti

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Anna Fagotti to discuss the results of the SCORPION trial. Dr. Fagotti is the lead author of "Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)", which is the Lead Article of IJGC’s November 2020 issue (https://ijgc.bmj.com/content/early/2020/10/07/ijgc-2020-001640). Dr. Fagotti is the Ovarian Cancer Unit Director at Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, Italy, as well as an Associate Professor of Obstetrics and Gynecology at Università Cattolica del Sacro Cuore. Additionally, she is PhD Faculty of Biotechnology at University of Perugia, ESGO Council Member and Chair of the Educational Committee, as well as an Associate Editor for IJGC. Highlights: 1. PDS and NACT ± IDS have superimposable median PFS and OS in patients with HTL ovarian cancer. 2. PDS has a higher rate of postoperative complications than IDS. 3. RT is the most powerful prognostic factor in AOC patients both at PDS and IDS"